Skip to main content

Table 5 Analysis of IBS-QOL Responsiveness

From: Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients

 

Treatment group

n

Mean change from baseline

Mean difference from placebo

t-Value

Degrees of freedom

p-Value

Effect sizes

d Pooled

d Placebo

IBS-QOL total score, Observed Data(a)

5 mg

66

19.73

2.02

0.64

189

0.522

0.09

0.09

25 mg

135

18.75

1.04

0.43

258

0.664

0.05

0.05

100 mg

130

25.25

7.54

3.10

253

0.002

0.39

0.33

200 mg

107

25.06

7.35

2.68

230

0.008

0.35

0.32

Placebo

125

17.70

      

IBS-QOL total score, Longitudinal Model(b)

5 mg

105

19.33

2.00

1.09

262

0.279

0.13

0.09

25 mg

167

18.46

1.13

0.67

324

0.507

0.07

0.05

100 mg

163

24.53

7.20

4.20

320

<.001

0.47

0.31

200 mg

160

23.33

6.00

3.64

317

<.001

0.41

0.26

Placebo

159

17.33

      
  1. Note: (a) Effect size estimates based on observed standard deviations (sPooled, sPlacebo) (b) Effect size estimates based on estimated standard deviations from a mixed-effects model for IBS-QOL total score with fixed effects of treatment, time, treatment by time interaction, and Baseline IBS-QOL total score and random effects for intercept and time σ ^ Pooled , σ ^ Placebo .